Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia

被引：45

作者：

Barbey, JT ^{[1
]}

Soignet, S

机构：

[1] Georgetown Univ, Washington, DC 20007 USA

[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

来源：

ANNALS OF INTERNAL MEDICINE | 2001年 / 135卷 / 09期

关键词：

D O I：

10.7326/0003-4819-135-9-200111060-00021

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：842 / 842

页数：1

共 2 条

[1] MORTALITY AND MORBIDITY IN PATIENTS RECEIVING ENCAINIDE, FLECAINIDE, OR PLACEBO - THE CARDIAC-ARRHYTHMIA SUPPRESSION TRIAL [J].

ECHT, DS ;

LIEBSON, PR ;

MITCHELL, LB ;

PETERS, RW ;

OBIASMANNO, D ;

BARKER, AH ;

ARENSBERG, D ;

BAKER, A ;

FRIEDMAN, L ;

GREENE, HL ;

HUTHER, ML ;

RICHARDSON, DW .

NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (12) :781-788

[2] Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia [J].

Ohnishi, K ;

Yoshida, H ;

Shigeno, K ;

Nakamura, S ;

Fujisawa, S ;

Naito, K ;

Shinjo, K ;

Fujita, Y ;

Matsui, H ;

Takeshita, A ;

Sugiyama, S ;

Satoh, H ;

Terada, H ;

Ohno, R .

ANNALS OF INTERNAL MEDICINE, 2000, 133 (11) :881-885

← 1 →